4,171 Shares in TransMedics Group, Inc. $TMDX Purchased by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 4,171 shares of the company’s stock, valued at approximately $559,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. OneDigital Investment Advisors LLC raised its stake in TransMedics Group by 52.6% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company’s stock worth $403,000 after purchasing an additional 2,065 shares in the last quarter. Principal Financial Group Inc. raised its stake in TransMedics Group by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company’s stock worth $13,350,000 after purchasing an additional 5,480 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in TransMedics Group in the 1st quarter worth about $291,000. New York State Teachers Retirement System raised its stake in TransMedics Group by 183.2% in the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company’s stock worth $1,477,000 after purchasing an additional 14,200 shares in the last quarter. Finally, Peregrine Capital Management LLC raised its stake in TransMedics Group by 3.4% in the 1st quarter. Peregrine Capital Management LLC now owns 68,390 shares of the company’s stock worth $4,601,000 after purchasing an additional 2,250 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on TMDX. Stifel Nicolaus began coverage on shares of TransMedics Group in a research report on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price for the company. Jefferies Financial Group began coverage on shares of TransMedics Group in a research report on Monday, October 13th. They issued a “buy” rating and a $145.00 target price for the company. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Monday, August 25th. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Evercore ISI began coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and an average target price of $127.18.

TransMedics Group Trading Up 0.2%

Shares of NASDAQ TMDX opened at $120.13 on Wednesday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $145.50. The firm has a 50 day moving average price of $116.15 and a two-hundred day moving average price of $114.35. The stock has a market cap of $4.10 billion, a P/E ratio of 62.24 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm had revenue of $157.37 million during the quarter, compared to analysts’ expectations of $146.64 million. During the same period in the prior year, the company posted $0.35 EPS. The company’s revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.